LONDON, July 25, 2017 /PRNewswire/ -- DAWNING study modified to allow patients the opportunity to receive dolutegravir-based regimens? ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive inte...
DARMSTADT, Germany, and NEW YORK, May 10, 2017 /PRNewswire/ -- * Second?approval?for BAVENCIO?in?less than two?months??? * Advanced urothelial carcinoma?is an aggressive disease with a high rate of recurrence??? Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Admi...
DARMSTADT, Germany and NEW YORK, March 24, 2017 /PRNewswire/ -- Not intended for UK-based media???? * Only?FDA-approved?treatment?for metastatic Merkel cell carcinoma, a rare and aggressive skin cancer??? ? ? * First indication for BAVENCIO,?a?human anti-PD-L1?antibody???? Merck and Pfizer ...
DARMSTADT, Germany and NEW YORK, Oct. 31, 2016 /PRNewswire/ -- Not intended for UK-based media? * If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma?? * The?Marketing Authorization Applicati...
LONDON , Aug. 16, 2016 /PRNewswire/ -- ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay?) and lamivudine (Epivir?) as a treatment for HIV-1 infection in adults who have not received prior antire...
LONDON, Feb. 25, 2016 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the 41 week phase IIa ECLAIR study, which evaluated the safety, tolerability, dosing and sat...
LONDON, Feb. 24, 2016 /PRNewswire/ --?ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) inBo...
LONDON, Feb. 23, 2016 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) today announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has completed two previously announced transactions with Bristol-Myers Squibb ...
LONDON and PITTSBURGH, Dec. 5, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine ...
LONDON, Aug. 23, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq? (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare's first dolutegravir-based ...